Floatz logo

Rufinamide

Peripheral Nerve Injuries

University of ZurichSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Peripheral Nerve Injuries cohort.

Asset / SponsorPhaseRating
Capsaicin
Astellas Pharma Europe Ltd.
Phase 4BBB
(±)-TRAMADOL
Astellas Pharma Inc
Phase 4BB
Pregabalin
Astellas Pharma Europe Ltd.
Phase 4BB

Same molecule, other indications

Rufinamide is also rated in:

Lennox-Gastaut syndromeDormant
BB
Indicative ·
70 / 100
View asset →
epilepsyDormant
BB
Indicative ·
65 / 100
View asset →
Mental RetardationDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →